html5-img
1 / 47

Henoch Schonlein Purpura (HSP)

Henoch Schonlein Purpura (HSP). O verview. Summary Epidemiology Etiology and Pathogenesis Clinical Manifestations Diagnosis Treatment. Henoch Schonlein Purpura (HSP). Most common systemic vasculitis in childre n 90% of cases occur in the pediatric group Etiology : Unknown

ashanti
Télécharger la présentation

Henoch Schonlein Purpura (HSP)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HenochSchonlein Purpura(HSP)

  2. Overview • Summary • Epidemiology • Etiology and Pathogenesis • Clinical Manifestations • Diagnosis • Treatment

  3. HenochSchonlein Purpura (HSP) • Most common systemic vasculitis in children • 90% of cases occur in the pediatric group • Etiology: Unknown • Pathogenesis: End organ IgA immune complex (IC) deposition • Complications: Renal

  4. HenochSchonlein Purpura (HSP) • Clinical Diagnosis: • Palpable purpura without thrombocytopenia • Abdominal pain • Renal disease • Arthritis • Treatment: Disease usually self limited and treatment is usually symptomatic

  5. Epidemiology • Disease of early childhood ages 3-15 • 20 per 100,000 in UK children < 17 years-old • 70 per 100,000 in UK children 4-6 years-old • No comparable data in adults, less common • Male : Female ratio 1.2- 1.8: 1 Arthritis Rheum 1997 May;40(5):859-64

  6. Epidemiology • Less common in African American children • More severe course in adults • More frequent and severe renal disease  requirement for more aggressive treatment • Seasonal variance occurs in the fall, winter and spring and is rare in summer

  7. Etiology • Unknown etiology! • Precipitating antigen may be infectious • Many cases follow upper respiratory infection (URI) • Example: identical twins following adenovirus infection: • HSP in one, IgA nephropathy in other J Pediatr 1985 Jan;106(1):27-32.

  8. Pathogenesis • Immune-complex (IC) mediated disease associated with Immunoglobin A (IgA) deposition • Characteristic findings is leukocytoclastic vasculitis (LCV)of post capillary venules • Accompanied by IgA deposition within affected organs • IC of IgA1 is the ONLY subtype • Immune complexes activate complement (alternative)

  9. Pathogenesis • Hinge region O-linked glycans of IgA1 are deficient in galactose and/or sialic acid content • Renal mesangial cells bind galactose/sialic acid deficient hinge regions • Berger’s disease (IgA nephropathy) also involves IgA1 exclusively

  10. Clinical Features • Classic Tetrad: May develop over days to weeks • Rash (100%) • Arthralgias (82%) • Abdominal pain (63%) • GI bleeding (33%) • Renal disease (40%) Medicine (Baltimore) 1999 Nov;78(6):395-409.

  11. Clinical Features • Presenting feature by % • Rash 74% • Arthralgias 15% • Abdominal pain 12%

  12. Classification Criteria ACR 1990 EULAR / PRES 2005 Palpable purpura without coagulopathy or decreased platelets AND Diffuse abdominal pain Arthritis or arthralgia Bopsy with IgA deposition • Palpable Purpura • Age at onset < 20 years • Acute abdominal pain • Biopsy: • Granulocytes in walls of small arterioles / venules • > or = 2 criteria • 90% Sensitivity/Specificity

  13. Palpable Purpura • Erythematous, macular or urticarial wheals  petechia/palpable purpura • NORMAL clotting studies and platelets • Appears in crops • Symmetric distribution • Gravity/pressure dependent areas such as lower extremities

  14. Palpable Purpura • Localized subcutaneous edema in dependent and periorbital areas seen in children < 3 years old • Differential diagnosis of palpable purpura: • Mixed Cryoglobulinemia • Hypersensitivity vasculitis

  15. Arthritis/Arthralgias • Occur in up to 84% of patients • Uncommon sole presenting symptom at presentation • Transient, migratory oligoarthritis (1-4 joints) • Lower extremities > upper extremity joints • More common in hips, knees and ankles • Non-destructive arthritis (no chronic damage)

  16. Arthritis/Arthralgias • Prominent periarticular swelling with no synovitis • Significant pain + limited range of motion • Differential diagnosis (DDx): • Juvenile Idiopathic arthritis (JIA) • Rheumatoid arthritis (RA) • Systemic Lupus Erytematous (SLE)

  17. Gastrointestinal (GI) Symptoms Mild Symptoms Severe Symptoms GI bleed Bowel ischemia and necrosis Intussusception Bowel perforation • Nausea / vomiting • Abdominal pain • Transient paralytic leus

  18. Gastrointestinal (GI) Symptoms • Develops typically within 8 days of the rash • GI symptoms precede the rash in 15-35% of cases • Abdominal pain = submucosal hemorrhage + edema • Guaiac + stool is seen in 56% of patient • Massive GI hemorrhage is rare • Purpuric lesions may be seen on endoscopy

  19. Intusseception • Most common gastrointestinal complication of HSP • Incidence of 3.5% • Edema and hemorrhage contributes to development • Limited to small bowel in 60% of cases • Initial screening test: Ultrasound • Differential diagnosis: Appendicitis

  20. Renal Disease • Occurs in 20-54 % of children (more prevalent in adults) • 2 days to 4 weeks after onset of systemic symptoms • Hematuria is most common presentation • With or without red blood cell (RBC) casts • Nephrotic range proteinuria, ↑ creatinine and or hypertension  ↑ risk of progressive disease (adults)

  21. Renal Disease • % of glomeruli with crescents has prognostic significance • > 50% • 37% progressed to end stage renal disease (ESRD) • 18% with chronic renal insufficiency (CRI) • Differential diagnosis: • Berger’s Disease

  22. Renal Disease • Correlation between disease severity and biopsy findings • Asymptomatic hematuria: focal mesangial proliferation • Proteinuria: cellular proliferation • Nephrotic range proteinuria: crescents J Am Soc Nephrol 1999 Dec;10(12):2637-44

  23. Scotum Involvement • 2-38% involvement • Presentation mimics testicular torsion • Pain, tenderness and swelling • Evaluate with ultrasound or radionuclide scanning • Testicular torsion will show ↓ blood flow versus normal blood flow in HSP

  24. Clinical Findings in Adults with HSP • Similar manifestations as in children • Two main differences between adults and children: • Intussusception is rare in adults • Adults have ↑ risk of developing significant renal involvement including end-stage renal disease

  25. Diagnosis • Clinical manifestations (know the Tetrad) • Classification criteria • Gold Standard is biopsy • Demonstration of LCV with IgA deposition = HSP

  26. Biopsy Diagnosis • Biopsy obtained in children: • Unusual presentation or significant renal disease • Biopsy in adults: • Due to lower incidence, confirmation by biopsy is more important

  27. Skin Biopsy • Superficial dermis biopsy sufficient • Goal to obtain skin lesions less than 24 hour-old • Leukocytoclastic vasculitis in post capillary venules with IgA deposition = pathognomonic of HSP

  28. Renal Biopsy • Obtain in severe renal involvement or uncertain diagnosis • Characterized by IgA deposition in mesangium • Immunoflorence studies  IgG, fibrin, C3 • Mesangial proliferation to crescentic glomerulonephritis (GN) • Biopsy generally parallels clinical disease severity

  29. Labs • No lab test is diagnostic for HSP • Labs obtained tend to be non-specific • Normal coagulation studies and platelets • This differentiates HSP from other diseases • Need to obtain renal function and urinalysis at a diagnosis

  30. Imaging Studies • Obtain in patients with significant abdominal symptoms • Plain abdominal X-ray: • May demonstrate dilated bowel loops • Ultrasound: • ↑ bowel wall thickness, hematomas and intussusception

  31. Treatment • Complete recovery 94% children, 89% of adults • Supportive treatment in vast majority • Rest • Hydration • NSAIDS

  32. Treatment • Hospitalization indicated: • Inability to maintain adequate hydration with oral intake • Severe abdominal pain • Significant gastrointestinal bleeding • Changes in mental status • Severe joint involvement limiting ambulation • Renal insufficiency (↑ Creatinine), HTN, nephrotic syndrome

  33. Treatment with Corticosteroids (CS) • Use is controversial • Benefits include: • Shortened duration of abdominal pain • ↓ risk of intussusception • ↓ risk of recurrence • ↓ risk of renal involvement

  34. Corticosteroids • Results of benefit mixed in studies • Absence of definitive evidence of long term benefits • Only used in patients with severe symptoms requiring hospitalization • Prednisone 1-2 mg/kg/day, max dose of 60-80 mg/day • Inflammation will be improved but the pathophysiology of the disease does not appear to be affected

  35. Specific Therapy: GI disease • Gastrointestinal • Corticosteroids not proven to decrease risk of intussusception • Using corticosteroids after intussusception has occurred may obscure the signs of compromised bowel viability Medicine (Baltimore) 1999 Nov;78(6):395-409.

  36. Specific Therapy: Renal disease • Should only be considered in patients with: • Marked proteinuria and/or impaired renal function • Therapies for cresentic nephritis: • High dose methylprednisolone  oral prednisone for 3 months has shown benefit • Azathioprine and corticosteroids • Cyclophosphamide

  37. Recurrent Disease • Recurrence occurs in 1/3rd of children • Occurs within 4 months of initial episode • Usually milder and briefer and occur in patients: • Nephritis • Evidence of acute inflammation • Patients who received corticosteroids

  38. Summary • Most common systemic vasculitis in children • 90% of cases occur in the pediatric group • Etiology: Unknown • Pathogenesis: End organ IgA immune complex (IC) deposition • Complications: Renal, GI

  39. Summary • Clinical Diagnosis: • Palpable purpura without thrombocytopenia • Abdominal pain • Renal disease • Arthritis • Treatment: Typically symptomatic and self limited • Unclear role of corticosteroids in TX • No specific agent proven efficacious for persistent renal disease

  40. References • Niaudet P, et al. Renal manifestations of Henoch-Schönlein purpura. Uptodate 2012. • Dedeoglu F, et al. Clinical manifestations and diagnosis of Henoch-Schönlein purpura. Uptodate 2012. • Dedeoglu F, et al. Management of Henoch-Schönlein purpura. Uptodate 2012.

  41. Questions?

More Related